Abstracts tagged "COVID-19"

Abstract Number: 0962 • ACR Convergence 2021
Association of Antiphospholipid Antibodies with Thromboembolic Events and Severe Outcomes in COVID-19
Arielle Mendel¹, Marvin Fritzler², Yvan St.Pierre¹, Joyce Rauch³, Sasha Bernatsky³ and Evelyne Vinet⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³McGill University, Montréal, QC, Canada, ⁴McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Although several studies indicate that patients with COVID-19 produce antiphospholipid antibodies (aPL), it is unclear which aPL subtype predominates and whether aPL correlates with…
Abstract Number: 1318 • ACR Convergence 2021
Interplay Between Covid-19 and Spondyloarthritis or Its Treatment
Richard Howard¹, Michael Weisman², Hedley Hamilton³, Cassie Shafer¹, Elin Aslanyan¹, John Reveille⁴, Kevin Winthrop⁵, Dongseok Choi⁵, Kimbery Ogle⁵, Sarah Siegel⁵, Emily Papaspyru³, Donna Grims¹ and James T. Rosenbaum⁶, ¹Spondylitis Association of America, Encino, CA, ²Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Any-3, London, United Kingdom, ⁴Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁵Oregon Health & Science University, Portland, OR, ⁶Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: The Covid-19 pandemic has been especially challenging for patients with inflammatory diseases including spondyloarthritis (SpA). Patients with rheumatic and musculoskeletal diseases (RMDs) remain at…
Abstract Number: 1537 • ACR Convergence 2021
Impact of COVID-19 Infection on Patient-Reported Outcomes in Rheumatic Disease Patients: A Cross Sectional Study
Elaine Husni¹, Cassandra Calabrese², Brittany Lapin¹, Elizabeth Kirchner³ and Leonard Calabrese¹, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland Heights, OH, ³CCF, Cleveland, OH
Background/Purpose: The persistence of symptoms following COVID 19 is an area of great interest yet remains poorly understood. Long COVID symptoms are dominated by fatigue…
Abstract Number: 1555 • ACR Convergence 2021
Clinical Outcomes of Coronavirus Disease-2019 (COVID-19) in Hospitalized Patients with Rheumatic and Musculoskeletal Diseases (RMD)
Ikwinder Kaur¹, Mohsin Mughal², Abdul Asbeutah³, Mili Kakadia², Reem Alhashemi⁴, Hasan Mirza⁵, Harjot Jagdey⁶, Rasha Alhashimi⁷, vishakha sirpal², Punit Jariwala² and Eugenio Capitle⁸, ¹Monmouth Medical Center, an affiliate of Rutgers health system, Long Branch, NJ, ²Monmouth Medical Center, Long Branch, NJ, ³University of Tennessee Health Science Center, Memphis, TN, ⁴Monmouth Medical Center, Long Branch, NJ, ⁵Berkshire Medical Center, Pittsfield, MA, ⁶BronxCare Hospital, Bronx, NY, ⁷BIDMC, Havard, Boston, MA, ⁸Rutgers New Jersey Medical School, New Brunswick, NJ
Background/Purpose: COVID-19 has been implicated in an exaggerated inflammatory response by activating both innate and adaptive immune responses. Rheumatic disease patients are a vulnerable population…
Abstract Number: 1596 • ACR Convergence 2021
Changes in Patient-Reported Outcome (PRO) Scores During the COVID-19 Pandemic: Data from the ArthritisPower Research Registry
Kelly Gavigan¹, Esteban Rivera¹, Jeffrey Curtis², Shilpa Venkatachalam¹, Laura Stradford³, David Curtis¹ and William Nowell¹, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Nyack, NY
Background/Purpose: The COVID-19 pandemic caused particular concern among patients with autoimmune and rheumatic disease (ARD) due to increased risk of infection, and heightened sense of…
Abstract Number: 1616 • ACR Convergence 2021
Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley
Sukesh Sukumaran¹, Reshma Patel² and Deepika Singh³, ¹Valley Children's Healthcare, Madera, CA, ²Valley Children's Hospital, Madera, CA, ³Valley Children Healthcare, Madera, CA
Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…
Abstract Number: 1938 • ACR Convergence 2021
A Phenome-Wide Association Study of Genes Associated with COVID-19 Severity Reveals Shared Genetics with Rheumatic Conditions
Anurag Verma¹, Noah Tsao¹, Lauren Thomann², Yuk-Lam Ho², Rotonya Carr¹, Dana crawford³, Jimmy efird⁴, Jennifer Huffman², Adriana Hung⁵, Kerry Ivey², Sudha Iyengar³, Michael Levin⁶, Shiuh-Wen luoh⁷, Julie Lynch⁸, Pradeep Natarajan⁹, Saiju Pyarajan¹⁰, alexander Bick¹¹, Lauren Costa², Giulio Genovese¹², Richard Hauger¹³, Ravi madduri¹⁴, Gita Pathak¹⁵, Renato polimanti¹⁵, Benjamin Voight¹, Marijana Vujkovic¹, Maryam Zekavat¹⁵, Hongyu Zhao¹⁵, Marylyn Ritchie¹, Kyong-Mi Chang¹⁶, Kelly Cho², Juan casas², Phil Tsao¹⁷, J. Michael Gaziano², Christopher ODonnell², Scott Damrauer¹ and Katherine Liao¹⁸, ¹University of Pennsylvania, Philadelphia, PA, ²VA Boston Healthcare System, Boston, MA, ³Case Western Reserve University, Cleveland, OH, ⁴DVAHCS, Durham, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶University of Pennsylvania, Philadelphia, ⁷Oregon Health & Science University, Portland, ⁸VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Partners, Boston, ¹¹Vanderbilt University, Nashville, TN, ¹²Harvard Medical School, Boston, MA, ¹³University of California San Diego, San Diego, CA, ¹⁴Argon National Lab, Chicago, IL, ¹⁵Yale University, New Haven, CT, ¹⁶VA Philadelphia, Philadelphia, PA, ¹⁷VA Palo Alto, Palo Alto, CA, ¹⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: Severe coronavirus disease 2019 (COVID-19) is associated with a broad range of clinical conditions. International efforts have led to the identification of risk alleles…
Abstract Number: 0084 • ACR Convergence 2021
COVID-19 Pneumonia in Two Hospitals: Similar Outcomes Despite Differential Use of Tocilizumab
Leanna Wise¹, Lauren Mathias², Wendy Mack², Aarya Kafi³, Yash Kothari², Omkar Rao³ and William Stohl⁴, ¹LAC+USC/Keck Medicine of USC, Pasadena, CA, ²University of Southern California, Los Angeles, CA, ³University of California San Diego, San Diego, CA, ⁴University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: A substantial number of patients with COVID-19 pneumonia develop a hyperinflammatory state. The anti-IL-6 receptor (IL-6R) mAb tocilizumab (TCZ) has been used in such…
Abstract Number: 0102 • ACR Convergence 2021
Differential Impact of TNFi, JAKi and Rituximab on the Outcome of SARS-CoV-2 Infection in RMD Patients
Anne Regierer¹, Rebecca Hasseli², Martin Schaefer¹, Bimba Franziska Hoyer³, Andreas Krause⁴, Hanns-Martin Lorenz⁵, Alexander Pfeil⁶, Jutta Richter⁷, Tim Schmeiser⁸, Anja Strangfeld⁹, Hendrik Schulze-Koops¹⁰, Reinhard Voll¹¹, Christof Specker¹² and Ulf Müller-Ladner¹³, ¹German Rheumatism Research Center, Berlin, Germany, ²Justus-Liebig-University Giessen, Bad Nauheim, Germany, ³Universittsklinikum Schleswig-Holstein, Kiel, Germany, ⁴Immanuel Hospital, Berlin, Germany, ⁵University Hospital Heidelberg Germany, Heidelberg, Germany, ⁶Friedrich Schiller University Jena, Jena, Germany, ⁷Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ⁸Private Practice, Cologne, Germany, ⁹Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ¹⁰Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹¹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹²Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ¹³JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany
Background/Purpose: Due to the impressive efforts of the global scientific rheumatology community, increasing evidence about inflammatory rheumatic and musculoskeletal diseases (RMD) specific risk factors in…
Abstract Number: 0152 • ACR Convergence 2021
Deep Learning-Derived Chest Radiograph Scores in COVID-19 in Rheumatic Disease Patients versus General Population Comparators
Naomi Patel¹, Kristin D'Silva¹, Matthew Li¹, Tiffany Hsu², Michael Di Iorio³, Xiaoqing Fu¹, Claire Cook⁴, Lauren Prisco⁵, Lily Martin⁶, Kathleen Vanni⁶, Alessandra Zaccardelli⁶, Yuqing Zhang⁷, Jayashree Kalpathy-Cramer¹, Jeffrey Sparks⁶ and Zachary Wallace⁸, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Jamaica Plain, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Pound Ridge, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Massachusetts General Hospital, Quincy, MA, ⁸Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with rheumatic diseases and COVID-19 may have higher risk of mechanical ventilation than those without rheumatic diseases. We compared COVID-19 lung disease between…
Abstract Number: 0631 • ACR Convergence 2021
Provider Assessment of Telehealth Utility During COVID-19
Catherine Howe¹, Isaac Smith¹, Robert Overton², Ricardo Henao², Nicoleta Economou-Zavlanos², Jayanth Doss³, Megan Clowse⁴ and David Leverenz³, ¹Duke University Hospital, Durham, NC, ²Duke Clinical Research Institute, Durham, NC, ³Duke University, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: The COVID-19 pandemic forced the provision of telehealth care to rheumatology patients with a broader range of diagnoses and disease activity than previously studied.…
Abstract Number: 0963 • ACR Convergence 2021
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRDs)
Gordon Lam¹, Andrew Laster², Sarah McCarter², Heather Gladue³, Ahmad Kashif², Erin Siceloff², Victoria Lackey³, Cheryl Robertson³, Ashley Toci² and Leonard Calabrese⁴, ¹Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, ²Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ³Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ⁴Cleveland Clinic, Cleveland, OH
Background/Purpose: AIIRD patients may have a blunted immune response to the COVID-19 vaccines, but this is largely uncharacterized as these individuals were not included in…
Abstract Number: 1411 • ACR Convergence 2021
Decreased Use of Ultrasound Fast-track Pathways of Giant Cell Arteritis Due to COVID-19 Pandemic: A Potential Risk for Permanent Visual Loss
Fernando Montero¹, Juan Molina², ISABEL CASTREJON³, Julia Martínez Barrio¹, Juan Carlos Nieto¹ and Jose Maria Alvaro-Gracia¹, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Maran, Madrid, Spain, ³Pfizer Spain, Chicago
Background/Purpose: The implementation of ultrasound (US) fast-track pathways (FTP), aiming at an early diagnosis of giant cell arteritis (GCA), has led to a decrease in…
Abstract Number: 1538 • ACR Convergence 2021
Adverse Events After SARS-CoV-2 Vaccination Among Rheumatology Outpatients in New York City
Medha Barbhaiya¹, Deanna Jannat-Khah¹, Jonah Levine¹, Huong Do¹, Lindsay Lally¹, Vivian Bykerk² and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: Vaccination against SARS-CoV-2 is important for patients with systemic rheumatic diseases (SRDs), who may be at increased risk of severe outcomes post-COVID-19 infection. However,…
Abstract Number: 1556 • ACR Convergence 2021
Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)
Ines Perez - Sancristobal¹, Dalifer Freites¹, Leticia Lopez Pedraza², Maria Paula Alvarez Hernandez¹, Jose Ignacio Colomer³, Alfredo Madrid - Garcia², Benjamin Fernandez¹, Cristina Vadillo¹, Luis Rodriguez Rodriguez⁴, Arkaitz Mucientes², Leticia Leon - Mateos² and Lydia Abasolo⁵, ¹Hospital Clínico San Carlos, Reumathology, Madrid, Madrid, Spain, ²Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Reumathology, Madrid, Spain, ³Fundación para la Investigación Biomedica, Reumathology, Madrid, Spain, ⁴Hospital Clinico San Carlos, Madrid, Spain, ⁵Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: In patients with rheumatic and musculoskeletal diseases (RMDs) and infected with Covid – 19, a) we want to assess the mortality rate (MR) related…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].